New Method Speeds Up Drug Development
In the laboratory of Bernhard Spingler (r.), trainee Philipp Nievergelt (l.) made an important contribution to determine the crystal structures of organic salts faster and easier. Credit: UZH
One of the key steps in developing new drugs is determining the atomic structure of its biologically active substances. This generally involves performing X-ray analyses of single crystal structures to determine the ingredient's detailed three-dimensional set-up. However, growing suitable single crystals is often a complex and time-consuming process.
Determining crystal structures more quickly and efficiently
A research group headed up by Bernhard Spingler, professor at the Department of Chemistry of the University of Zurich, has now modified a method that had previously been used exclusively for the crystallization of proteins, and successfully applied it to organic salts. The team was able to determine the crystal structures of several organic salts with significantly less time and effort. "As organic salts make up about 40 percent of all active pharmaceutical ingredients, this new method can greatly speed up the development of drugs," says Spingler.
Simplified screening of organic salts
The generation of solid salts of organic molecules is a key step in developing certain pharmaceutical ingredients. The positively and negatively charged particles that make up organic salts determine their properties, such as their solubility, crystal shape, ability to absorb water, melting point, and stability. The search for the ideal negatively charged anion to match the salt's positively charged cation has until now been a very resource-intensive process. Thanks to the semi-automatic combination of ion exchange screening and vapor diffusion for crystallization, this is not only done quicker and at lower costs. "We can now also determine the structures of the salt combinations directly after screening, since doing so only requires only very small amounts," adds crystallography expert Spingler.
Trainee achieves breakthrough
The breakthrough in developing the novel method was achieved by Philipp Nievergelt, a trainee who had spent 10 months in Bernhard Spingler's lab after graduating from Gymnasium. The successful junior researcher is listed as first author of the study and is now four semesters into his business chemistry studies at UZH. "The traineeship got me excited about lab work and encouraged me to continue doing research," explains Nievergelt.
This article has been republished from materials provided by University of Zurich. Note: material may have been edited for length and content. For further information, please contact the cited source.
“Lymphoma Micro-reactor” Targets Chemo-Resistant LymphomaNews
Researchers have developed a “lymphoma micro-reactor” device that exposes human lymphomas to fluid flow similar to that in the lymphatics and parts of the lymph node.READ MORE
Targeting Telomerase: A Therapeutic Strategy for Difficult-to-Treat MelanomaNews
Targeting telomerase was effective at killing NRAS-mutant melanoma cells, and the impact was further enhanced when the strategy was paired with an inhibitor of mitochondrial function, according to study results by The Wistar Institute published in Oncogene.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Structural and Molecular Biology 2018
Aug 22 - Aug 23, 2018
Asia Pacific Congress on Probiotics, Prebiotics and Nutrition
Oct 15 - Oct 16, 2018